Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?

Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$41.28M-25.1%	-$33M+4.0%	-$34.39M+17.0%	-$41.44M-15.4%	-$35.91M+4.4%
Depreciation and amortization	$98K-9.3%	$108K-10.0%	$120K-14.9%	$141K-9.6%	$156K-2.5%
Stock-based compensation	$6.12M-4.2%	$6.39M-9.8%	$7.08M-3.7%	$7.35M+7.6%	$6.83M+1.4%
Net cash from operating activities	-$36.88M-32.2%	-$27.9M+8.1%	-$30.37M-20.3%	-$25.25M+36.6%	-$39.82M+32.5%
Capital expenditures	——	$86K+258%	$24K+41.2%	$17K+54.5%	$11K-45.0%
Net cash from investing activities	$36.26M+23.1%	$29.47M—	——	——	-$43.66M-167%
Proceeds from issuance of debt	——	——	$191.11M—	——	$65.58M—
Net cash from financing activities	$3.22M—	——	$191.61M—	——	$65.66M+59,593%
Net increase (decrease) in cash	$2.49M+68.5%	$1.48M-99.1%	$166.63M+10,036%	-$1.68M+90.5%	-$17.62M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?: Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.